A study evaluating risk factor after treatment with Dasatinib for Cytomegalovirus (CMV) Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Phase of Trial: Phase IV
Latest Information Update: 30 Dec 2016
At a glance
- Drugs Dasatinib (Primary)
- Indications Acute lymphoblastic leukaemia; Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2016 New trial record